Skip to main content

Registry for Participants With Short Bowel Syndrome

Active, not recruiting · NCT01990040

Conditions: Short Bowel Syndrome

At a glance

Research payments reported, 2025
$805,826
U.S. investigators named
35
Sites paid
32
Planned or actual enrollment
1,806

About the trial

Sponsor
Shire (with Takeda Development Center Americas, Inc.)
Dates
Started 2014-06-23; completion 2032-06-30
Results posted
Not yet

This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.

From ClinicalTrials.gov, last updated 2026-09-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Takeda Pharmaceuticals U.S.A., Inc. reported $805,826 in research payments for this study in 2025 (586 payments).

Products named: Gattex

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.